News

. . .

		AboutBoard of directors
Management
Who we are
We build...CompaniesOverview
Internal Portfolio
Companies we’ve helped build
Accelerator
EcosystemsOverview
Innovation Centres
adMare Community
TalentOverview
Executive Institute
BIS Program
Experiential  Learning
adMare Institute
News
Events
CareersCulture
Open positions
Press Room
Contact us
Newsletter

	

			Terms and conditions
    
Français

		
adMare

News
vertical
adMare newsadMare insightsPortfolio companiesadMare AcademyAccelerator companies

						
						December 02 2024
Portfolio companies						
KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications
Read

						
						November 21 2024
Portfolio companies						
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Read

						
						November 15 2024
Portfolio companies						
Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing
Read

						
						November 12 2024
Portfolio companies						
Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing
Read

						
						October 25 2024
Portfolio companies						
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Read

						
						October 24 2024
Portfolio companies						
Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic
Read

						
						October 23 2024
adMare newsPortfolio companies						
Epitopea Closes USD $31 million Pre-Series A Financing
Read

						
						October 21 2024
Portfolio companies						
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
Read

						
						October 15 2024
Portfolio companies						
Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients
Read

						
						September 16 2024
adMare newsPortfolio companies						
Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec
Read

						
						August 27 2024
Portfolio companies						
Find Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Study of FTX-101 for the Treatment of Chronic Optic Neuropathy
Read

						
						July 23 2024
Portfolio companies						
Sutter Health Deploys World’s First Wearable Doppler Ultrasound Patch to Enhance Safety of ICU Patients
Read
  1  2  3  4  5  6
Newsletter

Stay up to date on the

latest adMare news
Subscribe
Français
Vancouver Innovation Centre2405 Wesbrook Mall

Vancouver, British Columbia, Canada

V6T 1Z3
T. 604.827.1147
Toronto OfficeMaRS Centre, West Tower

661 University Ave., Suite 405

Toronto, Ontario, Canada

M5G 1M1
T. 416.673.8100
Montreal Innovation Centre7171 Frederick-Banting

Montréal, Québec, Canada

H4S 1Z9
T. 514.375.3334
We

	build ...
Companies
Ecosystems
Talent
Who we are
adMare Institute
News
Events
Careers
Newsletter
Contact Us
Press Room
  
adMare

Community
Français
adMare BioInnovations Année all rights reserved - Privacy policy
Website by Riposte
 

                
                    Powered by 
                    
                
            

adMare News

KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic

Epitopea Closes USD $31 million Pre-Series A Financing

Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec

Find Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Study of FTX-101 for the Treatment of Chronic Optic Neuropathy

Sutter Health Deploys World’s First Wearable Doppler Ultrasound Patch to Enhance Safety of ICU Patients

Newsletter

Stay up to date on the latest adMare news

Vancouver Innovation Centre

T. 604.827.1147

Toronto Office

T. 416.673.8100

Montreal Innovation Centre

T. 514.375.3334

adMare
News

Stay up to date on the
latest adMare news